Evidence map›Paper›PMID 26497690›Full record

ArticleOncotarget2015

Adjuvant treatment with tumor-targeting Salmonella typhimurium A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model.

Takashi Murakami, Yukihiko Hiroshima, Ming Zhao, Yong Zhang, Takashi Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo, Robert M Hoffman

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Use ofFrontiers in oncology · 2021
    Review
  2. Perspectives on OncolyticFrontiers in immunology · 2021
    Review
  3. Bacteria-cancer interactions: bacteria-based cancer therapy.Experimental & molecular medicine · 2019
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Takashi MurakamiAntiCancer, Inc., San Diego, California, USA.
Yukihiko HiroshimaAntiCancer, Inc., San Diego, California, USA.
Ming ZhaoAntiCancer, Inc., San Diego, California, USA.
Yong ZhangAntiCancer, Inc., San Diego, California, USA.
Takashi ChishimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Kuniya TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Michael BouvetDepartment of Surgery, University of California, San Diego, California, USA.
Itaru EndoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Robert M HoffmanAntiCancer, Inc., San Diego, California, USA.
Yokohama City University · JPAntiCancer (United States) · USUniversity of California, San Diego · US

Funding

Fluorophore-Conjugated Antibodies for Imaging and Resection of GI TumorsR01CA142669 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2010 to 2015
$1.7M
Color-Coded Imaging of Pancreatic Cancer Microenvironment for Drug DiscoveryR01CA132971 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2009 to 2013
$1.7M
NCI NIH HHS CA132971NCI NIH HHS CA142669NCI NIH HHS R01 CA132971NCI NIH HHS R01 CA142669
6 · The paper itself

Abstract

Colon cancer liver metastasis is often the lethal aspect of this disease. Well-isolated metastases are candidates for surgical resection, but recurrence is common. Better adjuvant treatment is therefore needed to reduce or prevent recurrence. In the present study, HT-29 human colon cancer cells expressing red fluorescent protein (RFP) were used to establish liver metastases in nude mice. Mice with a single liver metastasis were randomized into bright-light surgery (BLS) or the combination of BLS and adjuvant treatment with tumor-targeting S. typhimurium A1-R. Residual tumor fluorescence after BLS was clearly visualized at high magnification by fluorescence imaging. Adjuvant treatment with S. typhimurium A1-R was highly effective to increase survival and disease-free survival after BLS of liver metastasis. The results suggest the future clinical potential of adjuvant S. typhimurium A1-R treatment after liver metastasis resection.

Indexed as

HepatectomyAnimalsBiological TherapyColonic NeoplasmsCombined Modality TherapyGreen Fluorescent ProteinsHT29 CellsHumansLiver NeoplasmsLuminescent ProteinsMice, NudeNeoplasm Recurrence, LocalRed Fluorescent ProteinSalmonella typhimuriumTime FactorsTransfectionGreen Fluorescent ProteinsLuminescent ProteinsRed Fluorescent Proteincolon cancerliver metastasisnude miceorthotopic modelsRFP

Identifiers

PMID26497690
PMCPMC4747193
OpenAlexW2187119365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.